Gordon Moe




Dr. Gordon Moe is a staff Cardiologist, a Heart Failure Specialist, and the current Director of the Heart Failure Program at St. Michael’s Hospital. In addition, he is a Professor of Medicine at the University of Toronto and a Clinician/Scientist at the Li Ka Shing Knowledge Institute. He was the past chair of the Canadian Cardiovascular Society Heart Failure Guidelines Committee and continues working as a member of the Primary Panel of the Committee. His clinical research involves assessing the use of biomarkers, including B-type natriuretic peptides and new biomarkers in the management of acute and chronic heart failure and the quality of care in heart failure. Dr. Moe served in numerous industry-sponsored and investigator-initiated clinical trials as principal investigator. He authored multiple peer-reviewed journals and continues to serve on the editorial board of the Canadian Journal of Cardiology, Journal of American College of Cardiology, and American Heart Journal, to name a few. More recently, he created the first Cardiac Amyloidosis Clinic at St. Michael’s Hospital and begins to play a leadership role in managing this condition in Ontario with new research and knowledge translation. Dr. Moe is one of the recipients of the Queen’s Diamond Jubilee Medal, Queen Elizabeth II (Distinction), in 2012 for his dedicated service to peers, community, and Canada.

Recent Publications

  1. Chu, JY, Moe, GW, Vyas, MV, Chen, R, Chow, CM, Gupta, M et al.. Epidemiology of COVID-19 and Its Cardiac and Neurologic Complications Among Chinese and South Asians in Ontario: Waves 1, 2, and 3. CJC Open. 2022;4 (10):894-904. doi: 10.1016/j.cjco.2022.06.008. PubMed PMID:36254328 PubMed Central PMC9568686.
  2. Merdad, A, Fam, NP, Connelly, KA, Peterson, MD, Moe, GW, Hassanin, M et al.. Outcomes of Transcatheter Edge-to-Edge Repair, Surgical and Medical Therapy in Combined Mitral and Tricuspid Regurgitation. JACC Cardiovasc Interv. 2022;15 (1):117-120. doi: 10.1016/j.jcin.2021.09.041. PubMed PMID:34991820 .
  3. Lee, C, Chow, CM, Yan, AT, Moe, GW, Tu, JV, Chu, JY et al.. Awareness of Warning Symptoms of Heart Disease and Stroke: Results of a Follow-up Study of the Chinese Canadian Cardiovascular Health Project. CJC Open. 2021;3 (6):741-750. doi: 10.1016/j.cjco.2021.01.014. PubMed PMID:34169253 PubMed Central PMC8209403.
  4. Chu, JY, Kaliwal, Y, Koh, M, Chen, R, Chow, CM, Ko, DT et al.. COVID-19 and its Cardiac and Neurological Complications among Ontario Visible Minorities. Can J Neurol Sci. 2022;49 (4):504-513. doi: 10.1017/cjn.2021.148. PubMed PMID:34162448 PubMed Central PMC8365110.
  5. Fuery, MA, Chouairi, F, Januzzi, JL, Moe, GW, Caraballo, C, McCullough, M et al.. Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. JACC Heart Fail. 2021;9 (7):497-505. doi: 10.1016/j.jchf.2021.02.011. PubMed PMID:33992564 .
  6. McDonald, M, Virani, S, Chan, M, Ducharme, A, Ezekowitz, JA, Giannetti, N et al.. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol. 2021;37 (4):531-546. doi: 10.1016/j.cjca.2021.01.017. PubMed PMID:33827756 .
  7. Writing Group, Virani, SA, Zieroth, S, Bray, S, Ducharme, A, Harkness, K et al.. The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. CJC Open. 2020;2 (3):151-160. doi: 10.1016/j.cjco.2020.03.001. PubMed PMID:32462129 PubMed Central PMC7242502.
  8. Rabi, DM, McBrien, KA, Sapir-Pichhadze, R, Nakhla, M, Ahmed, SB, Dumanski, SM et al.. Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2020;36 (5):596-624. doi: 10.1016/j.cjca.2020.02.086. PubMed PMID:32389335 .
  9. O'Meara, E, McDonald, M, Chan, M, Ducharme, A, Ezekowitz, JA, Giannetti, N et al.. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Can J Cardiol. 2020;36 (2):159-169. doi: 10.1016/j.cjca.2019.11.036. PubMed PMID:32036861 .
  10. Nerenberg, KA, Zarnke, KB, Leung, AA, Dasgupta, K, Butalia, S, McBrien, K et al.. Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2018;34 (5):506-525. doi: 10.1016/j.cjca.2018.02.022. PubMed PMID:29731013 .
Search PubMed

Affiliations & Other Activities

  • Director, Heart Failure Program and Biomarker Laboratory, Cardiology, St. Michael’s Hospital
  • Professor, Department of Medicine, St. Michael’s Hospital